Eur Rev Med Pharmacol Sci 2021; 25 (6): 2473-2474
DOI: 10.26355/eurrev_202103_25408

Comment on safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis

M. Ceccarelli, P. Pavone, E. Venanzi Rullo, G. Nunnari

Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Catania, Catania, Italy. emmanuele.venanzirullo@unime.it

Free PDF Download

To cite this article

M. Ceccarelli, P. Pavone, E. Venanzi Rullo, G. Nunnari
Comment on safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 6
Pages: 2473-2474
DOI: 10.26355/eurrev_202103_25408

Keywords Related articles:

  1. Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis
  2. Reply Letter – “Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis”
  3. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019
  4. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients
  5. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review